我們已在上線！進一步了解

Ocugen

OCGN

市值 US$2.65億

0.7803 USD

-0.0334

4.1%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

0.8025

+0.0222

2.85%

1天

-4.1%

5天

-18.49%

1個月

-21.84%

3個月

-43.04%

6個月

-59.57%

今年迄今

-43.46%

1年

-51.53%

5年

-90.55%

10年

-99.53%

關於： Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

員工： 116

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 9.1%

中性 81.8%

負面 9.1%

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for the treatment of Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical development program within The Bahamas' growing longevity and regenerative-medicine sector.

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to address blindness diseases, today announced the appointment of Jolanda Crombach, MSc PharmD, as General Manager of the Company's European affiliate. Ms. Crombach, an accomplished pharmaceutical executive with more than 20 years of industry experience, will lead the Company's newly established European affiliate, headquartered in Amsterdam, Netherlands.

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

Ocugen to Participate in Upcoming Scientific Conferences

MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences.

Ocugen to Participate in Upcoming Scientific Conferences

Ocugen to Participate in Upcoming October Investor and Industry Conferences

MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its executive leadership team will present at two upcoming investor and industry conferences.

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that OCU400 has been granted provisional approval and priority designation from the LARTA Board, the regulatory agency responsible for reviewing and approving longevity and regenerative therapy programs within the Commonwealth of The Bahamas. Ocugen will supply OCU400 through an EAP, with the goal of treating the first RP patient within 90 days, following full LARTA approval.

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances

Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion.

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances

Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical

Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal trial catalysts, and sufficient cash runway, despite high commercial and execution risk. Key upcoming catalysts include Phase 3 data for OCU400 and OCU410ST (Stargardt) in 2027 and a Phase 3 trial for OCU410 now FDA-cleared.

Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical

What's Happening With Ocugen Stock Thursday?

Shares of Ocugen Inc. (NASDAQ:OCGN) are remaining flat Thursday morning as investors continue to weigh disappointing interim clinical trial data.

What's Happening With Ocugen Stock Thursday?

查看新聞排名

價格圖表採用Lightweight Charts™實作